semaglutide april 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these Now that shortages of semaglutide

[10] [11] Phase 2 trial data published in the New England Journal of Medicine in 2023 (Jastreboff et al.) demonstrated substantial effects on body weight and metabolic parameters, though the full benefitrisk profile is still being established in ongoing Phase 3 trials

Produced in a facility which processes products containing nuts, milk, gluten, egg, soya, shell fish and peanuts

Presence or absence of fever

It has not been studied in its own clinical trials

This is why consistent monitoring of menstrual patterns, libido, mood, and labs matters: we need longterm registries that track these endpoints across years, not just weeks, to move uncertainty into evidence